Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1467)	5/26/2000 2:58:00 PM
From: Lighthouse	Respond to of 3202

Van Kasper goes "way out" on the limb upgrading INCY to Accumulate with a $60 price target. biz.yahoo.com Methodology a little different than my tastes. Van Kasper uses a price to growth ratio and relates that to other genomic companies. Unfortunately, the majority of "other" genomic companies operate on a far different business model than INCY. While a nice data point to have, PEG ratio's between very different companies would only be one facet of comparison. As Vector1 has pointed out INCY has a ton more revenue than most companies in this field thereby lowering its relative PEG. Anyway that is what their analyst is looking at. The JNJ article is a hint of what is up inside the forward looking labs around the world. I for one enjoy the peek. Big pharma views genomics as another important tool set to work with. Biotech, without the mega resouces may view INCY's data as a much more immediate critical element. I would like to see some color on the biotech side. Perhaps this trickle of information regarding INCY's utility will start to increase. Cheers,